TCGA-55-6983-01A-11R-1949-07
— · cohortA3
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA3
- subtype
- cohortA3
- age_years
- 81
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.510
- TGF_BETA_SIGNALING+0.350
- KRAS_SIGNALING_UP+0.320
- ALLOGRAFT_REJECTION+0.270
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- HEDGEHOG_SIGNALING+0.250
- ANGIOGENESIS+0.240
- COAGULATION+0.190
- ESTROGEN_RESPONSE_EARLY+0.190
- MYOGENESIS+0.190
Top 10 suppressed
- E2F_TARGETS-0.630
- G2M_CHECKPOINT-0.560
- MYC_TARGETS_V2-0.500
- MITOTIC_SPINDLE-0.400
- DNA_REPAIR-0.390
- MYC_TARGETS_V1-0.370
- INTERFERON_ALPHA_RESPONSE-0.310
- MTORC1_SIGNALING-0.300
- CHOLESTEROL_HOMEOSTASIS-0.210
- SPERMATOGENESIS-0.210
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-55-8207-01A-11R-2241-07 | — | cohortA1 | 0.851 |
| 2 | TCGA-A7-A5ZW-01A-12R-A29R-07 | — | A | 0.844 |
| 3 | TCGA-G2-A2EC-01A-11R-A180-07 | — | — | 0.835 |
| 4 | 20030069.LumA | — | A | 0.832 |
| 5 | C3L-03463 | — | cohortA3 | 0.830 |
| 6 | TCGA-CN-6019-01A-11R-1686-07 | — | — | 0.828 |
| 7 | TCGA-93-7348-01A-21R-2039-07 | — | cohortA1 | 0.824 |
| 8 | X1ecc3a65.9882.4182.bb55.887a9bb9fc6a | — | cohortMD2 | 0.822 |
| 9 | SRR8613790 | — | A | 0.814 |
| 10 | TCGA-H4-A2HO-01A-11R-A180-07 | — | — | 0.811 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 26 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.510 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.350 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.270 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.250 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.240 | Remibrutinib | — uncovered |
| COAGULATION | 0.190 | Binimetinib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.190 | Inavolisib | — uncovered |
| MYOGENESIS | 0.190 | Inavolisib | — uncovered |
| COMPLEMENT | 0.160 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.130 | Temsirolimus | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.130 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.120 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.110 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.110 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.070 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.070 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.070 | Inavolisib | — uncovered |
| PEROXISOME | 0.070 | Idelalisib | — uncovered |